Asian Pricing and Reimbursement
Ju Hyoung Lim, PhD
How to compete and succeed in a rapidly changing market
A land of pharma opportunity and financial challenges
Growing major trends are emerging across Asian healthcare markets. Rising incomes, increased government healthcare expenditure, higher life expectancies and a surge of chronic illnesses are boosting the demand for pharmaceutical products and services in the region. This sea of change is also being driven by multiple factors including government healthcare reforms, increasing Universal Health Coverage (UHC), the rise of private financing and heavy promotion of the generic market.
This offers a significant opportunity both for established pharmaceutical companies in the region who wish to continue to thrive and for those considering entering the Asian market. However, it also presents a unique set of regional challenges and commercial success will be dependent on understanding the complexities of the Asian pricing and reimbursement environment.
Opportunities within a changing Asian market
The Asian healthcare landscape is a dynamic one. The region consists of a wide diversity of healthcare markets in very different stages of development, particularly with regard to their healthcare infrastructure.
The healthcare environment within Asia is changing dramatically and spending in the region has shown an explosive rise in recent decades. Between 2009-2012 Asian markets showed the highest growth of per-capita healthcare spending in the world, at 38.8% of CAGR compared with the global average of 26.3%.1 The sharp increase of healthcare spending in this region can be explained by several factors, including growing economies, expansion of the middle class, the rise of chronic illness and increased life expectancy.
To meet this rapid growth, Asian healthcare systems will need to expand and adapt. As more countries implement healthcare reforms, leading to greater patient population coverage, countries across Asia will need to address pricing and reimbursement challenges to meet healthcare demands.
Ju Hyoung Lim, PhD
Ju has played a pivotal role within Deallus to expand our presence in Asian markets, driving business growth throughout Singapore, Japan, and China. Ju works closely with clients in order to manage and support both regional and global projects. He has extensive experience in competitive intelligence, portfolio planning, indication scoping, forecasting, product planning, and workshop design.
Peter Hempshall, CEO of Deallus, is partnering with Rita Numerof, Founder & President of Numerof & Associates, for a discussion series centered on the lasting impact that COVID-19 will have on business models in the healthcare industry. Tune in to be part of a discussion on how the pandemic has accelerated key market shifts, how organizations will need to operate differently, and what solutions can be offered for successfully moving businesses forward in this new reality.
We are very pleased to welcome Yacine Amrani to our Deallus team as Senior Principal. Yacine brings a strong background in Market Access, pricing and U.S. Managed Markets including extensive payer, access, pricing and reimbursement capabilities. Yacine has led engagements across multiple therapeutic areas both in the U.S and overseas for leading pharma players as well as biotech firms.
As the COVID-19 pandemic continues to impact patients, healthcare systems, and global economic outlooks, we focus on the key considerations and strategies for pharma companies when the data generation for possible therapies is becoming increasingly complex to analyze. There are several COVID-19 treatment and vaccine databases containing an aggregation of publicly-available information from validated sources detailing treatments and vaccines currently in development.
As COVID-19 continues to disrupt normalcy across the globe, China is responding with innovation in online health delivery and telemedicine. How has China encouraged telemedicine uptake? What are the factors contributing to China’s relatively quick utilization of telemedicine in the face of COVID-19? And what learnings can we gain from taking a closer look? We explore these questions in our latest addition to our COVID-19+Pharma Series.